Stock & analyst
information

This page contains a range of information related to Astellas’ stock performance, share status, shareholder return, dividend details, analyst coverage, issuer ratings, and more.

Stock chart

Performance

Current share status

As of March 31, 2025

Number of shareholders: 408,888

Common stock authorized: 9,000,000,000

Common stock issued: 1,809,663,075 

Current share status

Top ten (10) principal shareholders in the register of shareholders: 

  Name of shareholders Number of shares held (Thousand)  Percentage of shares held (%) 
1 The Master Trust Bank of Japan, Ltd.(trust account) 359,709 19.88
2 Custody Bank of Japan, Ltd. (trustaccount) 145,230  8.02
3 Goldman, Sachs & Co. Reg 60,729 3.35
4 State Street Bank and Trust Company505001 54,188 2.99 
5 Nippon Life Insurance Company 51,588 2.85 
6 State Street Bank West Client - Treaty505234 41,472 2.29
7 SMBC Nikko Securities Inc. 28,538 1.57
8 JPMorgan Securities Japan Co., Ltd. 27,503 1.52
9 JPMorgan Chase Bank 385781 26,382 1.45
10 State Street Bank and Trust Company505103 20,914 1.15

Number of shares held are presented by discarding the numbers down to the thousand, and percentage of shares are presented by discarding the numbers down to the third decimal.

Basic information about shares

Shareholder Return

Basic policy on shareholder return:

The Company works aggressively towards increasing enterprise value on a continual basis and, as a consequence, improves its return to shareholders. While putting priority on business investment to assure future growth, the Company strives to increase dividend payments stably and continuously based on its medium- to long-term profit growth on a consolidated basis. Further, the Company flexibly acquires its own shares whenever necessary to increase capital efficiency and shareholder return. 

1

Top priority is investment for business growth

2

Raise dividend level aligned with profit / cashflow plan and actual performance throughout CSP2021 period

3

Flexibly execute share buyback by excess cash

Shareholder Return 

IFRS
  Dividend (Unit: Yen / share)  
  Interim dividend  Year-end dividend  Total Annual dividend  DOE* (%)
FY2025
 39
(Planned) 39
(Planned) 78
(Planned)   
FY2024 37 37 74 8.5
FY2023 35 35 70 8.1
FY2022 30 30 60 7.3
FY2021 25 25 50 6.5
FY2020
 21 21 42 5.8
FY2019 20 20 40 5.9

FY2018 19 19 38 5.8
FY2017 18 18 36 5.7

as of July 7, 2025

List of analysts of securities companies and research companies who makerecommendations and reports of Astellas' performance, etc

Company name Person in charge
BofA Securities Japan Co., Ltd.  Koichi Mamegano 
Citigroup Global Markets Japan Inc.  Hidemaru Yamaguchi 
Daiwa Securities Co. Ltd.  Kazuaki Hashiguchi 
Goldman Sachs Japan Co., Ltd.  Akinori Ueda 
Jefferies Japan Limited  Stephen Barker 
JPMorgan Securities Japan Co., Ltd.  Seiji Wakao 
Macquarie Capital Securities (Japan) Limited  Tony Ren 
Mizuho Securities Co., Ltd.  Yuriko Ishida
Morgan Stanley MUFG Securities Co., Ltd.  Shinichiro Muraoka 
Nomura Securities Co., Ltd.  Hiroyuki Matsubara 
Sanford C. Bernstein Japan KK  Miki Sogi 
SMBC Nikko Securities Inc.  Hiroshi Wada 
UBS Securities Japan Co., Ltd.  Fumiyoshi Sakai 

Note: This list is based on the currently available information regarding coverage forAstellas by the securities analysts/researchers. The list may not be complete and issubject to change.

 

Please note that any opinions, estimates or forecasts regarding Astellas'performance, businesses, products, and technologies made by the analysts at listedabove or the analysts not listed above, are theirs alone and not those of Astellas orits management.

 

Astellas provides this information solely for the purpose of introducing theanalysts/researchers to the investors. Astellas does not imply its endorsement of orconcurrence with any information, estimates, opinions, recommendations andinformation by these analysts/researchers.

 

If you actually intend to trade stock, please make such stock traded in accordancewith your own judgment.

(As of March 23, 2021) 

Astellas' status in Action to Implement Management that is Conscious of Cost of Capital and Stock Price is as follows.

Analysis of current situation

  • Recognized that awareness of cost of capital and stock price is essential for sustainable growth and increased corporate value
  • Aiming to ensure return on capital in excess of cost of capital, WACC is calculated and verified on a regular basis and used in business investment decision-making after a clear assessment of the cost of capital
  • On the other hand, it is recognized that stock prices in the pharmaceutical sector are heavily influenced by business performance and the future pipeline value
  • Implement management based on the evaluation of future pipeline value as an indicator to realize medium- and long-term corporate value enhancement, rather than capital profitability indicators such as ROE and ROIC, which are calculated as actual values for a single fiscal year

Planning

  • A medium-term plan “Corporate Strategic Plan 2021” was announced in May 2021. The Performance Goals set are ‘Revenue', ‘Pipeline Value' and ‘Core Operating Profit Margin’
  • Aspire to be recognized as a company with a market capitalization exceeding 7 trillion yen by achieving the Performance Goals above 
  • Revised and disclosed capital allocation policy in line with Corporate Strategic Plan 2021 (see figure below for details) 
  • When opportunities for capital investment to realize future growth are identified, raise funds as necessary, while carefully assessing and managing the appropriate level of capital reserves 
  • Maintain a balanced capital structure necessary to ensure future cash flows and a stable operational foundation when implementing large-scale acquisitions 

Initiatives

  • Adopt Performance-linked Stock Compensation Scheme (measurement index: TSR*) as medium- to long-term incentive remuneration for Directors and Top Management, and establish a system that contributes to the enhancement of corporate value and shareholder value 
  • Review the corporate value (theoretical value) calculated from the "pipeline value" and other factors on a regular basis, monitor progress, and implement business decisions necessary for enhancing corporate value 
  • When making business investments, evaluate them by calculating NPV using the DCF method with WACC, and make decisions aimed at achieving a return that exceeds the cost of capital 
  • To achieve appropriate market valuation and share price, including future growth potential, and to reduce the cost of capital, promote proactive investor relations activities to engage with investors and enhance comprehensive information disclosure
  • In accordance with the capital allocation policy, raise the dividend level aligned with profit / cashflow plan and actual performance, and flexibly execute share buybacks
  • In accordance with the increase in interest-bearing debt associated with the acquisition of Iveric Bio, carry out appropriate debt management with a focus on cash flow and aim to promptly restore financial soundness 

: Total Shareholder Return. Total investment yield for shareholders, including capital gains and dividends 

Cautionary statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas' stock.

  • changes in general economic conditions in, and the laws and regulations relating to, Astellas' markets, 
  • currency exchange rate fluctuations, 
  • delays in new product launches, 
  • the inability of Astellas to market existing and new products effectively, 
  • Astellas' ability to continue research and develop products accepted by customers in highly competitive markets and 
  • infringements of Astellas' intellectual property rights.

(2) The pages include the information regarding pharmaceuticals including the ones under development, however, they are not intended for advertisement or medical advice at all.

 

(3) Addition, change or deletion of the information may occur at anytime without notice. 

Keep exploring

Astellas employees work on a laptop and examine the company’s strong financial results.

Financial Results Library

Two Astellas employees shake hands, symbolizing the company’s goal to maximize its return to shareholders.

Contact Us

(For Institutional Investors and Securities Analysts)